Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 1/2020

Open Access 01-01-2020 | Multiple Myeloma

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

Published in: Quality of Life Research | Issue 1/2020

Login to get access

Abstract

Background

Carfilzomib and daratumumab are licensed in relapsed/refractory multiple myeloma (RRMM), but no head-to-head trials have been conducted.

Methods

We used data from dossiers prepared for the German Federal Joint Committee based on two phase III randomized trials of carfilzomib-based therapies (ASPIRE, ENDEAVOR) and two of daratumumab-based therapies (POLLUX, CASTOR) to conduct a descriptive assessment of health-related quality of life (HRQoL). HRQoL was assessed using the European Organisation for Research and Treatment of Cancer 30-item HRQoL Questionnaire, with hazard ratios calculated for carfilzomib- and daratumumab-based therapy versus comparators for time to HRQoL deterioration of ≥ 10 points. Analyses were also conducted on data from the EORTC 20-item myeloma-specific questionnaire, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale, and the visual analog scale of the EuroQoL 5-dimension, 5-level questionnaire, where results for these instruments were available. As the designs and patient population of the four trials were similar but not identical, the analysis included only indirect, descriptive comparisons.

Results

Compared with lenalidomide/dexamethasone, median time to deterioration in global health status/QoL was longer for carfilzomib-based therapy versus control, but similar for daratumumab-based therapy and control. Compared with bortezomib/dexamethasone, time to deterioration was significantly longer for carfilzomib-based therapy versus control for global health status/QoL and numerous functional and symptom subscales. HRQoL measurement is feasible in large RRMM populations.

Conclusion

Descriptive assessment of HRQoL data suggests potential benefits for carfilzomib-based over daratumumab-based therapy.
Appendix
Available only for authorised users
Literature
1.
Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A., Fonseca, R., et al. (2017). Therapy for relapsed multiple myeloma: Guidelines from the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clinic Proceedings,92(4), 578–598.CrossRef
2.
3.
4.
Fonseca, R., Abouzaid, S., Bonafede, M., Cai, Q., Parikh, K., Cosler, L., et al. (2017). Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia,31(9), 1915–1921.CrossRef
5.
Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W. J., Oriol, A., et al. (2017). Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial. The lancet Oncology,18(10), 1327–1337.CrossRef
6.
Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., et al. (2018). Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood,131(3), 301–310.CrossRef
7.
Landgren, O., & Iskander, K. (2017). Modern multiple myeloma therapy: Deep, sustained treatment response and good clinical outcomes. Journal of Internal Medicine,281(4), 365–382.CrossRef
8.
Siegel, D. S., Dimopoulos, M. A., Ludwig, H., Facon, T., Goldschmidt, H., Jakubowiak, A., et al. (2018). Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology,36(8), 728–734.CrossRef
9.
10.
11.
Gulbrandsen, N., Hjermstad, M. J., & Wisloff, F. (2004). Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. European Journal of Haematology,72(3), 172–180.CrossRef
12.
Johnsen, A. T., Tholstrup, D., Petersen, M. A., Pedersen, L., & Groenvold, M. (2009). Health related quality of life in a nationally representative sample of haematological patients. European Journal of Haematology,83(2), 139–148.CrossRef
13.
Ramsenthaler, C., Osborne, T. R., Gao, W., Siegert, R. J., Edmonds, P. M., Schey, S. A., et al. (2016). The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer,16, 427.CrossRef
14.
Sonneveld, P., Verelst, S. G., Lewis, P., Gray-Schopfer, V., Hutchings, A., Nixon, A., et al. (2013). Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia,27(10), 1959–1969.CrossRef
15.
Delforge, M., Dhawan, R., Robinson, D., Jr., Meunier, J., Regnault, A., Esseltine, D. L., et al. (2012). Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: Results from the VISTA trial. European Journal of Haematology,89(1), 16–27.CrossRef
16.
Delforge, M., Minuk, L., Eisenmann, J. C., Arnulf, B., Canepa, L., Fragasso, A., et al. (2015). Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: Lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica,100(6), 826–833.CrossRef
17.
Leleu, X., Masszi, T., Bahlis, N. J., Viterbo, L., Baker, B., Gimsing, P., et al. (2018). Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. American Journal of Hematology,93(8), 985–993.CrossRef
18.
Song, K. W., Dimopoulos, M. A., Weisel, K. C., Moreau, P., Palumbo, A., Belch, A., et al. (2015). Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. Haematologica,100(2), e63–e67.CrossRef
19.
Weisel, K., Dimopoulos, M., Song, K. W., Moreau, P., Palumbo, A., Belch, A., et al. (2015). Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial. Clinical Lymphoma, Myeloma & Leukemia,15(9), 519–530.CrossRef
20.
Maes, H., & Delforge, M. (2015). Optimizing quality of life in multiple myeloma patients: Current options, challenges and recommendations. Expert Review of Hematology,8(3), 355–366.CrossRef
21.
Carlson, J. J., Guzauskas, G. F., Chapman, R. H., Synnott, P. G., Liu, S., Russo, E. T., et al. (2018). Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the United States. Journal of Managed Care & Specialty Pharmacy,24(1), 29–38.CrossRef
22.
Sparano, F., Cavo, M., Niscola, P., Caravita, T., & Efficace, F. (2018). Patient-reported outcomes in relapsed/refractory multiple myeloma: A systematic review. Supportive Care in Cancer,26(7), 2075–2090.CrossRef
23.
Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hajek, R., et al. (2016). Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study. The lancet Oncology,17(1), 27–38.CrossRef
24.
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Spicka, I., Oriol, A., et al. (2015). Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. New England Journal of Medicine,372(2), 142–152.CrossRef
25.
26.
27.
de Weers, M., Tai, Y. T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C., et al. (2011). Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. Journal of Immunology,186(3), 1840–1848.CrossRef
28.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., et al. (2016). Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine,375(14), 1319–1331.CrossRef
29.
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., et al. (2016). Daratumumab, bortezomib, and dexamethasone for multiple myeloma. New England Journal of Medicine,375(8), 754–766.CrossRef
30.
31.
32.
33.
34.
Dimopoulos, M. A., Moreau, P., Nahi, H., Plesner, T., Goldschmidt, H., Suzuki, K., et al. (2017). Efficacy and safety of daratumumab, lenalidomide, and dexamethasone versus Rd alone in relapsed or refractory multiple myeloma: Updated analysis of pollux. Haematologica,102, 108–109.CrossRef
35.
Ludwig, H., Moreau, P., Dimopoulos, M. A., Mateos, M. V., Kaiser, M. F., Feng, S., et al. (2016). Health related quality of life results from the open-label, randomized, phase III ENDEAVOR trial evaluating carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood,128(Suppl 22), 3309.CrossRef
36.
Stewart, A. K., Dimopoulos, M. A., Masszi, T., Spicka, I., Oriol, A., Hajek, R., et al. (2016). Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Journal of Clinical Oncology,34(32), 3921–3930.CrossRef
37.
Weisel, K., Lentzsch, S., Mateos, M. V., Hungria, V., Munder, M., Nooka, A., et al. (2017). Efficacy and safety of daratumumab, bortezomib and dexamethasone (DVD) versus bortezomib and dexamethasone (VD) in relapsed or refractory multiple myeloma (RRMM): Updated analysis of CASTOR. Haematologica,102, 168–169.CrossRef
38.
Shih, C. L., Chen, C. H., Sheu, C. F., Lang, H. C., & Hsieh, C. L. (2013). Validating and improving the reliability of the EORTC QLQ-C30 using a multidimensional Rasch model. Value in Health,16(5), 848–854.CrossRef
39.
Kvam, A. K., Fayers, P. M., & Wisloff, F. (2011). Responsiveness and minimal important score differences in quality-of-life questionnaires: A comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. European Journal of Haematology,87(4), 330–337.CrossRef
40.
Snyder, C. F., Blackford, A. L., Sussman, J., Bainbridge, D., Howell, D., Seow, H. Y., et al. (2015). Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients’ supportive care needs. Quality of Life Research,24(5), 1207–1216.CrossRef
41.
Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011). Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Journal of Clinical Oncology,29(1), 89–96.CrossRef
42.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology,16(1), 139–144.CrossRef
43.
Richardson, P. G., Schlossman, R. L., Roy, A. N., Panneerselvam, A., Acharyya, S., Sopala, M., et al. (2018). Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥ 2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. British Journal of Haematology,181(5), 628–636.CrossRef
44.
Dubois, D., Dhawan, R., van de Velde, H., Esseltine, D., Gupta, S., Viala, M., et al. (2006). Descriptive and prognostic value of patient-reported outcomes: The bortezomib experience in relapsed and refractory multiple myeloma. Journal of Clinical Oncology,24(6), 976–982.CrossRef
45.
Siegel, D., Ludwig, H., Moreau, P., Mateos, M.-V., Niesvizky, R., & Chng, W. J., et al. (2018). Association of clinical response with survival and quality of life after carfilzomib and dexamethasone (Kd56) treatment in the phase III ENDEAVOR trial. Presented at the European Hematology Association Annual Meeting, Stockholm, Sweden.
46.
Berkowitz, A., & Walker, S. (2012). Bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Clinical Journal of Oncology Nursing,16(1), 86–89.CrossRef
47.
Kvam, A. K., & Waage, A. (2015). Health-related quality of life in patients with multiple myeloma—does it matter? Haematologica,100(6), 704–705.CrossRef
Metadata
Title
Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data
Publication date
01-01-2020
Published in
Quality of Life Research / Issue 1/2020
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-019-02307-5

Other articles of this Issue 1/2020

Quality of Life Research 1/2020 Go to the issue

OriginalPaper

Parental perception of child health status and quality of life associated with overweight and obesity in early childhood

OriginalPaper

Orthostatic hypotension and health-related quality of life among community-living older people in Korea

OriginalPaper

Health-related quality of life in children after laparoscopic gastrostomy placement

OriginalPaper

Quality of life in nursing home residents with pain: pain interference, depression and multiple pain-related diseases as important determinants

Review

Outcome measurement instruments for peripheral vascular malformations and an assessment of the measurement properties: a systematic review

OriginalPaper

Relationships between cognition, function, and quality of life among HIV+ Canadian men